In vitro Function

INTERCEPT is not approved for sale in the US and certain other countries.

Effect of INTERCEPT Treatment on Functional Characteristics of Platelets

Apheresis Platelets

5-Day Storage
- Janetzko K, Corash L, Lin L et al. In vitro function of double-dose platelets treated with the pathogen inactivation Helinx technology. In: Holick MF, ed. Biologic Effects of Light 2001. Boston, MA: Kluwer Academic Publishers, 2002:313-23.
  > View abstract
- Janetzko K, Klinger M, Mayaudon V et al. Storage characteristics of split double-dose platelet concentrates derived from apheresis and treated with amotosalen hydrochloride and UVA light for pathogen inactivation. Transfusion Medicine and Hemotherapy 2002;29(4):193-98.
  > View abstract
7-Day Storage
- Cognasse F, Osselaer J-C, Payrat JM et al. Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion 2008;48(5):809-813.
  > View abstract
5-Day and 7-Day Storage
- Cognasse F, Payrat JM, Corash L et al. Platelet components associated with acute transfusion reations: the role of platelet-derived soluble CD40 Ligand. Blood 2008;112(12):4779-4780.
  > View abstract

Buffy Coat-Derived Platelets

5-Day Storage
- Bruchmuller I, Losel R, Bugert P et al. Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. Platelets 2005;16(8):441-5.
  > View abstract
7-Day Storage
- Lozano M, Galan A, Mazzara R et al. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCI and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007;47(4):666-71.
  > View abstract
- Knutson F, Alfonso R, Dupuis K et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platetlet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000;78(4):209-16.
  > View abstract
- Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000;79(4):206-14.
  > View abstract
- van Rhenen DJ, Vermeij J, Mayaudon V et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000;79(4):206-14.
  > View abstract

Platelet-Rich Plasma (PRP)-Derived Platelets

5-Day & 7-Day Storage Comparison
- Wagner SJ, Skripchenko A, Myrup A et al. Evaluation of in vitro storage properties of pre-storage pooled whole blood derived platelets suspended in 100% plasma and treated with amotosalen and UVA light. Transfusion 2009;49(4):704-10.
  > View abstract

Apheresis & Pooled Buffy Coat Platelets

Chavarin P, Cognasse F, Argaud C et al. SHORT REPORT: In vitro assessment of apheresis and pool buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System). Vox Sang 2011;100:247-249.
> View abstract

Fresh Frozen Plasma (FFP)

Irsch J, Pinkoski L, Corash L et al. INTERCEPT Plasma: comparability to conventional FFP based on preservation of functionality and activation status – an in vitro analysis. Vox Sang 2010;98(1):47-55.
> View abstract
De Valensart N, Rapaille A, Goossenaerts E et al. Study of coagulation function in thawed apheresis plasma for photochemical treatment by amotosalen and UVA. Vox Sang 2009;96:213-18.
> View abstract
Schlenke P, Hervig T, Isola H et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 2008:48(4):206-14.
> View abstract

Cryosupernatant (CSP) Prepared from FFP

Yarranton H, Lawrie AS, Mackie IJ et al. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion 2005;45(9):1453-8.
> View abstract